Nachrichten zur UroGen Pharma Ltd Aktie

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to…

Urogen Pharma: Neue Blasenkrebsmedikamente sollen für 69 % Umsatzplus pro Jahr sorgen

Urogen erzielt seit dem Jahr 2020 jährlich steigende Umsätze. Seit 2022 spiegelt sich dies in einem dauerhaften Anstieg des Aktienkurses…

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to…

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly…

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

UroGen Pharma: Lessons Learned And Future Outlook

…

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. (URGN) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…

URGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against UroGen Pharma Ltd.

Robbins LLP is Investigating Allegations that UroGen Pharma Ltd. (URGN) Failed to Conduct a Proper Trial for its Lead Drug…

Kirby McInerney LLP Reminds UroGen Pharma Ltd. (URGN) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors who…

UroGen Pharma Ltd. Investors: Please contact the Portnoy Law Firm to recover your losses. July 28, 2025 Deadline to file Lead Plaintiff Motion.

Investors can contact the law firm at no cost to learn more about recovering their losses…

Nachrichten zur UroGen Pharma Ltd Aktie

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

Urogen Pharma: Neue Blasenkrebsmedikamente sollen für 69 % Umsatzplus pro Jahr sorgen

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm

UroGen Pharma: Lessons Learned And Future Outlook

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. (URGN) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

URGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against UroGen Pharma Ltd.

Kirby McInerney LLP Reminds UroGen Pharma Ltd. (URGN) Investors of Class Action Filing and Encourages Investors to Contact the Firm

UroGen Pharma Ltd. Investors: Please contact the Portnoy Law Firm to recover your losses. July 28, 2025 Deadline to file Lead Plaintiff Motion.

UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But Its Not Over, Either

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?

Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates

UroGen Pharma: Choice Based On Near-Term High-Value PDUFA

UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript

UroGen Pharma: There Is Some Potential Here

UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript

UroGen Pharma stock maintains target post-offering By Investing.com

UroGen Pharma commences public offering of ordinary shares

UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?

UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript

Urogen Pharma executive sells shares worth over $168k By Investing.com

UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript

Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates

dpa-AFX ProFeed